Skip to main content
. 2012 May 9;7(5):e36545. doi: 10.1371/journal.pone.0036545

Figure 3. Effect of inhibiting CXCL8/CXCR2 signaling upon the efficacy of anti-metabolites in metastatic prostate cancer cells.

Figure 3

(A) Graphs illustrating cell count assay data, determined from the treatment of PC3 cells (left panel) or LNCaP cells (right panel) with increasing concentrations of either 5-FU, in the absence or presence of the CXCR2 receptor antagonist, AZ10397767. AZ10397767 was administered at a final concentration of 20 nM. Cell counts were taken 72 hours post-treatment with the anti-metabolite. Cell count data was analyzed using the non-linear regression function of GraphPad Prism, using a sigmoidal one-site curve fit equation. Data points shown are the mean ± S.E.M. value of four independent experiments. (B) Bar graph illustrating the effect of using siRNA to knockdown CXCR1 and CXCR2 expression upon the cytotoxicity of 1 µM 5-FU in PC3 (left panel) and LNCaP cells (right panel). Data points shown are the mean ± S.E.M. value of four independent experiments. (C) Bar graph presenting the level of apoptotic cells in drug-treated PC3 (left panel) and LNCaP (right panel) cell populations. Data shows the sub G0/G1-cell population determined by flow cytometry analysis following treatment with increasing concentrations of 5-FU, in the absence and presence of the CXCR2 receptor antagonist, AZ10397767.